PortalPublikationenUpdate Breast Cancer 2020 Part 3 - Early Breast Cancer

Update Breast Cancer 2020 Part 3 - Early Breast Cancer

Standard

Update Breast Cancer 2020 Part 3 - Early Breast Cancer. / Huober, Jens; Schneeweiss, Andreas; Hartkopf, Andreas D; Müller, Volkmar; Lux, Michael P; Janni, Wolfgang; Ettl, Johannes; Belleville, Erik; Thill, Marc; Fasching, Peter A; Kolberg, Hans-Christian; Schulmeyer, Carla E; Welslau, Manfred; Overkamp, Friedrich; Tesch, Hans; Fehm, Tanja N; Lüftner, Diana; Schütz, Florian; Wöckel, Achim.

in: GEBURTSH FRAUENHEILK, Jahrgang 80, Nr. 11, 11.2020, S. 1105-1114.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Huober, J, Schneeweiss, A, Hartkopf, AD, Müller, V, Lux, MP, Janni, W, Ettl, J, Belleville, E, Thill, M, Fasching, PA, Kolberg, H-C, Schulmeyer, CE, Welslau, M, Overkamp, F, Tesch, H, Fehm, TN, Lüftner, D, Schütz, F & Wöckel, A 2020, 'Update Breast Cancer 2020 Part 3 - Early Breast Cancer', GEBURTSH FRAUENHEILK, Jg. 80, Nr. 11, S. 1105-1114. https://doi.org/10.1055/a-1270-7208

APA

Huober, J., Schneeweiss, A., Hartkopf, A. D., Müller, V., Lux, M. P., Janni, W., Ettl, J., Belleville, E., Thill, M., Fasching, P. A., Kolberg, H-C., Schulmeyer, C. E., Welslau, M., Overkamp, F., Tesch, H., Fehm, T. N., Lüftner, D., Schütz, F., & Wöckel, A. (2020). Update Breast Cancer 2020 Part 3 - Early Breast Cancer. GEBURTSH FRAUENHEILK, 80(11), 1105-1114. https://doi.org/10.1055/a-1270-7208

Vancouver

Huober J, Schneeweiss A, Hartkopf AD, Müller V, Lux MP, Janni W et al. Update Breast Cancer 2020 Part 3 - Early Breast Cancer. GEBURTSH FRAUENHEILK. 2020 Nov;80(11):1105-1114. https://doi.org/10.1055/a-1270-7208

Bibtex

@article{41db8e88caa34441b0003d16ef35fcfd,
title = "Update Breast Cancer 2020 Part 3 - Early Breast Cancer",
abstract = "The treatment of patients with early breast cancer has always been characterised by escalation by new therapies and de-escalation through identification of better treatment regimens or introduction of better tools to estimate prognosis. Efforts in some of these areas in the last few years have led to solid data. The results of the large studies of de-escalation through use of multi-gene tests are available, as are the results of some studies that investigated the new anti-HER2 substances T-DM1 and pertuzumab in the early treatment situation. Several large-scale studies examining the role of CDK4/6 inhibitors will soon be concluded so innovations can be anticipated in this area also. This review article will summarise and classify the results of the latest publications.",
author = "Jens Huober and Andreas Schneeweiss and Hartkopf, {Andreas D} and Volkmar M{\"u}ller and Lux, {Michael P} and Wolfgang Janni and Johannes Ettl and Erik Belleville and Marc Thill and Fasching, {Peter A} and Hans-Christian Kolberg and Schulmeyer, {Carla E} and Manfred Welslau and Friedrich Overkamp and Hans Tesch and Fehm, {Tanja N} and Diana L{\"u}ftner and Florian Sch{\"u}tz and Achim W{\"o}ckel",
note = "The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).",
year = "2020",
month = nov,
doi = "10.1055/a-1270-7208",
language = "English",
volume = "80",
pages = "1105--1114",
journal = "GEBURTSH FRAUENHEILK",
issn = "0016-5751",
publisher = "Georg Thieme Verlag KG",
number = "11",

}

RIS

TY - JOUR

T1 - Update Breast Cancer 2020 Part 3 - Early Breast Cancer

AU - Huober, Jens

AU - Schneeweiss, Andreas

AU - Hartkopf, Andreas D

AU - Müller, Volkmar

AU - Lux, Michael P

AU - Janni, Wolfgang

AU - Ettl, Johannes

AU - Belleville, Erik

AU - Thill, Marc

AU - Fasching, Peter A

AU - Kolberg, Hans-Christian

AU - Schulmeyer, Carla E

AU - Welslau, Manfred

AU - Overkamp, Friedrich

AU - Tesch, Hans

AU - Fehm, Tanja N

AU - Lüftner, Diana

AU - Schütz, Florian

AU - Wöckel, Achim

N1 - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

PY - 2020/11

Y1 - 2020/11

N2 - The treatment of patients with early breast cancer has always been characterised by escalation by new therapies and de-escalation through identification of better treatment regimens or introduction of better tools to estimate prognosis. Efforts in some of these areas in the last few years have led to solid data. The results of the large studies of de-escalation through use of multi-gene tests are available, as are the results of some studies that investigated the new anti-HER2 substances T-DM1 and pertuzumab in the early treatment situation. Several large-scale studies examining the role of CDK4/6 inhibitors will soon be concluded so innovations can be anticipated in this area also. This review article will summarise and classify the results of the latest publications.

AB - The treatment of patients with early breast cancer has always been characterised by escalation by new therapies and de-escalation through identification of better treatment regimens or introduction of better tools to estimate prognosis. Efforts in some of these areas in the last few years have led to solid data. The results of the large studies of de-escalation through use of multi-gene tests are available, as are the results of some studies that investigated the new anti-HER2 substances T-DM1 and pertuzumab in the early treatment situation. Several large-scale studies examining the role of CDK4/6 inhibitors will soon be concluded so innovations can be anticipated in this area also. This review article will summarise and classify the results of the latest publications.

U2 - 10.1055/a-1270-7208

DO - 10.1055/a-1270-7208

M3 - SCORING: Journal article

C2 - 33173238

VL - 80

SP - 1105

EP - 1114

JO - GEBURTSH FRAUENHEILK

JF - GEBURTSH FRAUENHEILK

SN - 0016-5751

IS - 11

ER -